We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Automation Technology Selection Vital to Pharmaceutical and Biotech Industry Transformation

By LabMedica International staff writers
Posted on 04 Aug 2009
Automation expenditures in the pharmaceutical and biotech industry are expected to exceed US$3 billion by 2012, according to a new market report. More...


"Even with tightening budgets and the current financial crisis, the market for automation products and systems in the pharmaceutical and biotech industry continues to be moderate to strong. However, much of the current automation focuses on projects with immediate return on investments, projects that are the result of consolidation of manufacturing operations, and standardization of applications across the entire enterprise,” stated principal analyst for the CPG Industries John Blanchard, the principal author of ARC's (Dedham, MA, USA) new market report.

The four major areas of focus in pharmaceutical and biotech manufacturing are manufacturing productivity, flexibility, and service; the new scientific risk-based approach to regulatory compliance; reducing the cost and time of technology transfer; and ensuring product quality, safety, security, and delivery. The industry has also expressed concern over how it is going to support the ever-increasing level of automation with increasingly limited technical resources.

Over-investing has left big pharmaceutical companies with surplus manufacturing capacity at the same time R&D pipelines are drying up, regulatory barriers are delaying new approvals, and many of the blockbuster products are losing patent protection, according to the report. Discovering and commercializing new drug products remains the cornerstone of the industry. As new drug lifecycles continue to decrease and drug development expenses continue to rise, shortening time-to-commercialization is vital. However, traditional industry growth drivers of R&D and sales and marketing are slowing. Competition is intense. Active pharmaceutical ingredient (API) and excipient manufacturing and sourcing have become global. This is placing new emphasis on manufacturing to drive margin and growth. The Darwinian concept of "adapt or die” is on the mind of every senior executive; and proper selection and deployment of automation technology have become vital to success, according to the market research.

There are several reasons why production management software and analytics software are two of the fastest growing automation technologies being deployed by users, according to the report. Some suppliers have analytics that help reduce production cycle time and throughput. Others have analytics that can evaluate numerous solvent extraction schemes, reducing the number of experiments performed during the drug development phase.

Some suppliers have a strong presence in one or two geographic regions. Others have a strong presence on all four geographic regions, including a strong support infrastructure. Less presence in a geographic region can be an opportunity for the supplier. However, user manufacturers must evaluate such a supplier's regional support capabilities and commitment to their industry needs. The Latin American market is the fastest growing, but also a small market. Asia is the second fastest growing market and growing in market share, according to ARC analysts. India and China are playing a significant role in this market in terms of automation expenditures, customer relationship management (CRM), and contract manufacturing organization (CMO) capabilities, and domain expert information technology (IT) services. Acquisitions continue in 2009; however, acquisitions are one of several factors inhibiting deployment of new automation products and systems.

The ARC Advisory Group is a research and advisory firm for manufacturing, energy, and supply chain solutions. The company's coverage of technology from sensors and automation to production, design, and business systems makes it focused for business and IT executives worldwide.

Related Links:

ARC Advisory Group



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.